TCT 2019 | PARTNER 3: Obvious Short-Term Quality of Life Improvement, but What Happens Afterwards?

Courtesy of SBHCI.

Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation.

Highlights TCT 2019

This work, presented at the TCT 2019 Scientific Sessions and simultaneously published in JACC, analyzes precisely that: short- and long-term quality of life of patients who underwent transcatheter aortic valve replacement vs. surgery.

This analysis included 1000 low-risk patients with severe aortic stenosis who were randomized to balloon-expandable valve vs. surgery between 2016 and 2017.


Read also: TCT 2019 | EURO-CTO: Results at 3 Years of CTO Recanalization vs. Optimal Medical Treatment.


Quality of life was measured at baseline, 1, 6, and 12 months by means of the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF-36, and EQ-5D.

At one month from the procedure, results showed that patients who underwent transcatheter aortic valve replacement had much better scores than patients who underwent surgery (p < 0.0001).

At 6 and 12 months, such difference remained in favor of the balloon-expandable valve, but the curves were closer, narrowing the gap (p < 0.04).

The ratio of patients with excellent results was higher with TAVR, both at 6 months (90.3% vs. 85.3%; p = 0.03) and at 12 months (87.3% vs. 82.8%; p = 0.07).

Conclusion

Patients with severe aortic stenosis and low surgical risk who undergo transcatheter aortic valve replacement with a balloon-expandable valve have better quality of life scores, both in the short and in the long term, compared with surgery.

Courtesy of SBHCI.

Link to the SBHCI publication HERE

partner3-tct2019

Original Title: PARTNER 3: Health Status Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low Surgical Risk.

Author of the Original Article: Suzanne J. Baron.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...